The direct-to-consumer emergency treatment for an opioid overdose is intended to broaden availability
THURSDAY, June 18, 2026 (HealthDay News) — The U.S. Food and Drug Administration has approved another over-the-counter intranasal naloxone product, Rextovy (naloxone hydrochloride), for the emergency treatment of opioid overdose.
The 4-mg nasal spray is available for purchase by consumers without a prescription in pharmacies, convenience stores, and online. The product”s packaging includes five-step pictorial directions, including calling 911 after giving the first dose.
When regaining consciousness after the overdose reversal, some people may experience symptoms such as shaking, sweating, nausea, or feeling angry. The product is safe to use even if it is uncertain whether opioids are the cause of the overdose.
“Reducing opioid overdose deaths is a top priority for FDA,” Mike Davis M.D., Ph.D., from the FDA Center for Drug Evaluation and Research, said in a statement. “Today”s approval of an additional over-the-counter naloxone nasal spray helps broaden access and offers an additional option for consumers. Empowering people without medical training to take immediate action with these products has been proven to save lives.”
Nonprescription approval of Rextovy was granted to Amphastar Pharmaceuticals.
IV Iron Dextran Cost-Effective for Managing Iron-Deficiency Anemia 
Over-the-Counter Naloxone Shows Limited Uptake 
OTC Oral Contraceptive Pills Improve Access to Effective Contraception 
Dietary Nitrate From Beetroot Juice Promising for Pregnant Women With CKD 
Wildfires Now Top Source of Unhealthy Air for Pregnant Women in U.S. 
Alcohol Use Among Pregnant Women Has Increased Since 2011 
Sugar Restriction in First 1,000 Days From Conception Linked to Lower Risk for Dementia 
